Zealand Pharma As Stock Probability of Future Pink Sheet Price Finishing Over 103.00
| ZLDPF Stock | USD 101.61 0.64 0.63% |
Zealand |
Zealand Pharma Target Price Odds to finish over 103.00
The tendency of Zealand Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 103.00 or more in 90 days |
| 101.61 | 90 days | 103.00 | over 95.37 |
Based on a normal probability distribution, the odds of Zealand Pharma to move over $ 103.00 or more in 90 days from now is over 95.37 (This Zealand Pharma AS probability density function shows the probability of Zealand Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Zealand Pharma AS price to stay between its current price of $ 101.61 and $ 103.00 at the end of the 90-day period is about 1.21 .
Assuming the 90 days horizon Zealand Pharma has a beta of 0.46. This usually means as returns on the market go up, Zealand Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Zealand Pharma AS will be expected to be much smaller as well. Additionally Zealand Pharma AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Zealand Pharma Price Density |
| Price |
Predictive Modules for Zealand Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zealand Pharma AS. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Zealand Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Zealand Pharma is not an exception. The market had few large corrections towards the Zealand Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Zealand Pharma AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Zealand Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 0.46 | |
σ | Overall volatility | 9.90 | |
Ir | Information ratio | -0.14 |
Zealand Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zealand Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zealand Pharma AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Zealand Pharma AS generated a negative expected return over the last 90 days | |
| Zealand Pharma AS has high historical volatility and very poor performance | |
| The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M. | |
| Zealand Pharma AS has accumulated about 864.44 M in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.68. | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors |
Zealand Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Zealand Pink Sheet often depends not only on the future outlook of the current and potential Zealand Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zealand Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 43.2 M |
Zealand Pharma Technical Analysis
Zealand Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Zealand Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Zealand Pharma AS. In general, you should focus on analyzing Zealand Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Zealand Pharma Predictive Forecast Models
Zealand Pharma's time-series forecasting models is one of many Zealand Pharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Zealand Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Zealand Pharma AS
Checking the ongoing alerts about Zealand Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Zealand Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Zealand Pharma AS generated a negative expected return over the last 90 days | |
| Zealand Pharma AS has high historical volatility and very poor performance | |
| The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M. | |
| Zealand Pharma AS has accumulated about 864.44 M in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.68. | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors |
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.